Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Antiepileptic medication
Antiseizure medication
Brain injury
Dilantin
Electroencephalography
Epilepsy
Guideline
Keppra
Levetiracetam
Outcome
Phenytoin
Prevention
Prophylactic
Prophylaxis
Recommendation
Seizure
Trauma
Traumatic brain injury
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
05 Feb 2024
05 Feb 2024
Historique:
received:
14
11
2023
accepted:
20
11
2023
medline:
6
2
2024
pubmed:
6
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
There is practice heterogeneity in the use, type, and duration of prophylactic antiseizure medications (ASMs) in patients with moderate-severe traumatic brain injury (TBI). We conducted a systematic review and meta-analysis of articles assessing ASM prophylaxis in adults with moderate-severe TBI (acute radiographic findings and requiring hospitalization). The population, intervention, comparator, and outcome (PICO) questions were as follows: (1) Should ASM versus no ASM be used in patients with moderate-severe TBI and no history of clinical or electrographic seizures? (2) If an ASM is used, should levetiracetam (LEV) or phenytoin/fosphenytoin (PHT/fPHT) be preferentially used? (3) If an ASM is used, should a long versus short (> 7 vs. ≤ 7 days) duration of prophylaxis be used? The main outcomes were early seizure, late seizure, adverse events, mortality, and functional outcomes. We used Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to generate recommendations. The initial literature search yielded 1998 articles, of which 33 formed the basis of the recommendations: PICO 1: We did not detect any significant positive or negative effect of ASM compared to no ASM on the outcomes of early seizure, late seizure, adverse events, or mortality. PICO 2: We did not detect any significant positive or negative effect of PHT/fPHT compared to LEV for early seizures or mortality, though point estimates suggest fewer late seizures and fewer adverse events with LEV. PICO 3: There were no significant differences in early or late seizures with longer versus shorter ASM use, though cognitive outcomes and adverse events appear worse with protracted use. Based on GRADE criteria, we suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence). If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration (≤ 7 days, weak recommendation, low quality of evidence).
Sections du résumé
BACKGROUND
BACKGROUND
There is practice heterogeneity in the use, type, and duration of prophylactic antiseizure medications (ASMs) in patients with moderate-severe traumatic brain injury (TBI).
METHODS
METHODS
We conducted a systematic review and meta-analysis of articles assessing ASM prophylaxis in adults with moderate-severe TBI (acute radiographic findings and requiring hospitalization). The population, intervention, comparator, and outcome (PICO) questions were as follows: (1) Should ASM versus no ASM be used in patients with moderate-severe TBI and no history of clinical or electrographic seizures? (2) If an ASM is used, should levetiracetam (LEV) or phenytoin/fosphenytoin (PHT/fPHT) be preferentially used? (3) If an ASM is used, should a long versus short (> 7 vs. ≤ 7 days) duration of prophylaxis be used? The main outcomes were early seizure, late seizure, adverse events, mortality, and functional outcomes. We used Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to generate recommendations.
RESULTS
RESULTS
The initial literature search yielded 1998 articles, of which 33 formed the basis of the recommendations: PICO 1: We did not detect any significant positive or negative effect of ASM compared to no ASM on the outcomes of early seizure, late seizure, adverse events, or mortality. PICO 2: We did not detect any significant positive or negative effect of PHT/fPHT compared to LEV for early seizures or mortality, though point estimates suggest fewer late seizures and fewer adverse events with LEV. PICO 3: There were no significant differences in early or late seizures with longer versus shorter ASM use, though cognitive outcomes and adverse events appear worse with protracted use.
CONCLUSIONS
CONCLUSIONS
Based on GRADE criteria, we suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence). If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration (≤ 7 days, weak recommendation, low quality of evidence).
Identifiants
pubmed: 38316735
doi: 10.1007/s12028-023-01907-x
pii: 10.1007/s12028-023-01907-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Neurocritical Care Society.
Références
Mee H, Kolias AG, Chari A, Ercole A, Lecky F, Turner C, et al. Pharmacological management of post-traumatic seizures in adults: current practice patterns in the UK and the Republic of Ireland. Acta Neurochir. 2019;161(3):457–64.
pubmed: 30276544
doi: 10.1007/s00701-018-3683-9
Huijben JA, Volovici V, Cnossen MC, Haitsma IK, Stocchetti N, Maas AIR, et al. Variation in general supportive and preventive intensive care management of traumatic brain injury: a survey in 66 neurotrauma centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Crit Care. 2018;22(1):90.
pubmed: 29650049
pmcid: 5898014
doi: 10.1186/s13054-018-2000-6
Hickman ZL, Spielman LA, Barthelemy EJ, Choudhri TF, Engelman B, Giwa AO, et al. International survey of antiseizure medication use in patients with complicated mild traumatic brain injury: a New York Neurotrauma Consortium Study. World Neurosurg. 2022;6:66.
Naidech AM, Beaumont J, Muldoon K, Liotta EM, Maas MB, Potts MB, et al. Prophylactic seizure medication and health-related quality of life after intracerebral hemorrhage. Crit Care Med. 2018;46(9):1480–5.
pubmed: 29923930
pmcid: 6095719
doi: 10.1097/CCM.0000000000003272
Dikmen SS, Machamer JE, Winn HR, Anderson GD, Temkin NR. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000;54(4):895–902.
pubmed: 10690983
doi: 10.1212/WNL.54.4.895
Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA. 1991;265(10):1271–7.
pubmed: 1995974
doi: 10.1001/jama.1991.03460100073027
GRADE. Available from: https://www.gradeworkinggroup.org/ .
Schunemann HJB, J.; Guyatt, G.; Oxman, A. GRADE Handbook 2022. Available from: https://gdt.gradepro.org/app/handbook/handbook.html .
GRADE Guidelines Workshop + focus on implementation. Available from: https://gradeconf.org/2022-11/ .
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400.
pubmed: 21194891
doi: 10.1016/j.jclinepi.2010.09.012
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–7.
pubmed: 3363593
doi: 10.1161/01.STR.19.5.604
Evaluation of the Disability Determination Process for Traumatic Brain Injury in Veterans. Washington, DC; 2019.
Higgins JPS, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor. Cochrane handbook for systematic reviews of interventions version 63: Cochrane; 2022.
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.
pubmed: 27733354
pmcid: 5062054
doi: 10.1136/bmj.i4919
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
pubmed: 21195583
doi: 10.1016/j.jclinepi.2010.04.026
Dewidar O, Lotfi T, Langendam MW, Parmelli E, Saz Parkinson Z, Solo K, et al. Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med. 2022;6:66.
Inglet S, Baldwin M, Quinones AH, Majercik S, Collingridge DS, MacDonald J. Seizure prophylaxis in patients with traumatic brain injury: a single-center study. Cureus. 2016;8(8): e753.
pubmed: 27688990
pmcid: 5037062
Khor D, Wu J, Hong Q, Benjamin E, Xiao S, Inaba K, et al. Early seizure prophylaxis in traumatic brain injuries revisited: a prospective observational study. World J Surg. 2018;42(6):1727–32.
pubmed: 29159600
doi: 10.1007/s00268-017-4373-0
Ohimor SF, Falcone RE. Phenytoin prophylaxis in posttraumatic head injury. J Pharm Technol. 1996;12:160–4.
doi: 10.1177/875512259601200410
Pruitt P, Naidech A, Van Ornam J, Borczuk P. Seizure frequency in patients with isolated subdural hematoma and preserved consciousness. Brain Inj. 2019;33(8):1059–63.
pubmed: 31007086
doi: 10.1080/02699052.2019.1606446
Rish BL, Caveness WF. Relation of prophylactic medication to the occurrence of early seizures following craniocerebral trauma. J Neurosurg. 1973;38(2):155–8.
pubmed: 4632829
doi: 10.3171/jns.1973.38.2.0155
Sundararajan K, Milne D, Edwards S, Chapman MJ, Shakib S. Anti-seizure prophylaxis in critically ill patients with traumatic brain injury in an intensive care unit. Anaesth Intensive Care. 2015;43(5):646–51.
pubmed: 26310417
doi: 10.1177/0310057X1504300515
Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323(8):497–502.
pubmed: 2115976
doi: 10.1056/NEJM199008233230801
Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of prophylactically administered phenytoin to prevent early posttraumatic seizures. J Neurosurg. 1983;58(2):231–5.
pubmed: 6848680
doi: 10.3171/jns.1983.58.2.0231
Zangbar B, Khalil M, Gruessner A, Joseph B, Friese R, Kulvatunyou N, et al. Levetiracetam prophylaxis for post-traumatic brain injury seizures is ineffective: a propensity score analysis. World J Surg. 2016;40(11):2667–72.
pubmed: 27307089
doi: 10.1007/s00268-016-3606-y
Glaser AC, Kanter JH, Martinez-Camblor P, Taenzer A, Anderson MV, Buhl L, et al. The effect of antiseizure medication administration on mortality and early posttraumatic seizures in critically Ill older adults with traumatic brain injury. Neurocrit Care. 2022;37(2):538–46.
pubmed: 35641806
doi: 10.1007/s12028-022-01531-1
Pease M, Zaher M, Lopez AJ, Yu S, Egodage T, Semroc S, et al. Multicenter and prospective trial of anti-epileptics for early seizure prevention in mild traumatic brain injury with a positive computed tomography scan. Surg Neurol Int. 2022;13:241.
pubmed: 35855176
pmcid: 9282794
doi: 10.25259/SNI_38_2022
Patanwala AE, Kurita A, Truong E. Low-dose levetiracetam for seizure prophylaxis after traumatic brain injury. Brain Inj. 2016;30(2):156–8.
pubmed: 26619246
doi: 10.3109/02699052.2015.1089596
Vespa PM, Nuwer MR, Nenov V, Ronne-Engstrom E, Hovda DA, Bergsneider M, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg. 1999;91(5):750–60.
pubmed: 10541231
pmcid: 4347935
doi: 10.3171/jns.1999.91.5.0750
Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, et al. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Arch Neurol. 2012;69(10):1290–5.
pubmed: 22777131
pmcid: 4798941
doi: 10.1001/archneurol.2012.445
Wohns RN, Wyler AR. Prophylactic phenytoin in severe head injuries. J Neurosurg. 1979;51(4):507–9.
pubmed: 113510
doi: 10.3171/jns.1979.51.4.0507
Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of prophylactically administered phenytoin to prevent late posttraumatic seizures. J Neurosurg. 1983;58(2):236–41.
pubmed: 6848681
doi: 10.3171/jns.1983.58.2.0236
Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743–8.
pubmed: 15159471
doi: 10.1212/01.WNL.0000125184.88797.62
Scozzafava J, Hussain MS, Brindley PG, Jacka MJ, Gross DW. The role of the standard 20 minute EEG recording in the comatose patient. J Clin Neurosci. 2010;17(1):64–8.
pubmed: 19683448
doi: 10.1016/j.jocn.2009.03.008
Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy. 2011;31(10):934–41.
pubmed: 21950640
doi: 10.1592/phco.31.10.934
Ohman K, Kram B, Schultheis J, Sigmon J, Kaleem S, Yang Z, et al. Evaluation of levetiracetam dosing strategies for seizure prophylaxis following traumatic brain injury. Neurocrit Care. 2022;6:66.
MedDRA. MedDRA History. Available from: https://www.meddra.org/about-meddra/history .
Van Norman GA. Data safety and monitoring boards should be required for both early- and late-phase clinical trials. JACC Basic Transl Sci. 2021;6(11):887–96.
pubmed: 34869954
pmcid: 8617574
doi: 10.1016/j.jacbts.2021.09.005
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165–72.
pubmed: 19898966
doi: 10.1007/s12028-009-9304-y
Caballero GC, Hughes DW, Maxwell PR, Green K, Gamboa CD, Barthol CA. Retrospective analysis of levetiracetam compared to phenytoin for seizure prophylaxis in adults with traumatic brain injury. Hosp Pharm. 2013;48(9):757–61.
pubmed: 24421550
pmcid: 3857128
doi: 10.1310/hpj4809-757
Gabriel WM, Rowe AS. Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury. Ann Pharmacother. 2014;48(11):1440–4.
pubmed: 25169249
doi: 10.1177/1060028014549013
Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013;74(3):766–71; discussion 71–3.
Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008;25(4):E3.
pubmed: 18828701
pmcid: 3705765
doi: 10.3171/FOC.2008.25.10.E3
Kancharla TRRV, Mohan R, Nagesh A. Comparing the efficacy of phenytoin, levetiracetam and sodium valproate in prevention of post-traumatic seizures in brain injury. Int Res J Pharm. 2019;10(4):66.
doi: 10.7897/2230-8407.1004142
Khan SA, Bhatti SN, Khan AA, Khan Afridi EA, Muhammad G, Gul N, et al. Comparison of efficacy of phenytoin and levetiracetam for prevention of early post traumatic seizures. J Ayub Med Coll Abbottabad. 2016;28(3):455–60.
pubmed: 28712212
Kruer RM, Harris LH, Goodwin H, Kornbluth J, Thomas KP, Slater LA, et al. Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. J Crit Care. 2013;28(5):883e9–13.
Radic JA, Chou SH, Du R, Lee JW. Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis. Neurocrit Care. 2014;21(2):228–37.
pubmed: 24549935
pmcid: 10627505
doi: 10.1007/s12028-013-9951-x
Younus SM, Basar S, Gauri SA, Khan AA, Imran M, Abubakar S, et al. Comparison of phenytoin versus levetiracetam in early seizure prophylaxis after traumatic brain injury, at a Tertiary Care Hospital in Karachi, Pakistan. Asian J Neurosurg. 2018;13(4):1096–100.
pubmed: 30459875
pmcid: 6208194
doi: 10.4103/ajns.AJNS_125_17
Temkin NR, Dikmen SS, Anderson GD, Wilensky AJ, Holmes MD, Cohen W, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91(4):593–600.
pubmed: 10507380
doi: 10.3171/jns.1999.91.4.0593
Nguyen JV, Yaw T, Gratton H. Incidence of neurobehavioral side effects associated with levetiracetam compared to phenytoin in traumatic brain injury patients. Brain Inj. 2021;35(8):902–6.
pubmed: 34027761
doi: 10.1080/02699052.2021.1927184
Harris L, Hateley S, Tsang KT, Wilson M, Seemungal BM. Impact of anti-epileptic drug choice on discharge in acute traumatic brain injury patients. J Neurol. 2020;267(6):1774–9.
pubmed: 32130500
pmcid: 7293662
doi: 10.1007/s00415-020-09769-5
Kancharla TR. Comparing the efficacy of phenytoin, levetiracetam and sodium valproate in prevention of post-traumatic seizures in brain injury. Int Res J Pharm. 2019;10(4):156–60.
doi: 10.7897/2230-8407.1004142
Kumar S, Bharti AK, Prasad RS, Kumari S, Singh A, Yadav G. Efficacy of phenytoin for 7 days versus 21 days as prophylactic anticonvulsant in traumatic brain injury patients—a comparative study. J Fam Med Prim Care. 2022;11(8):4805–10.
doi: 10.4103/jfmpc.jfmpc_486_22
Struck AF, Ustun B, Ruiz AR, Lee JW, LaRoche SM, Hirsch LJ, et al. Association of an electroencephalography-based risk score with seizure probability in hospitalized patients. JAMA Neurol. 2017;74(12):1419–24.
pubmed: 29052706
pmcid: 5822188
doi: 10.1001/jamaneurol.2017.2459
Struck AF, Tabaeizadeh M, Schmitt SE, Ruiz AR, Swisher CB, Subramaniam T, et al. Assessment of the validity of the 2HELPS2B score for inpatient seizure risk prediction. JAMA Neurol. 2020;77(4):500–7.
pubmed: 31930362
pmcid: 6990873
doi: 10.1001/jamaneurol.2019.4656
Fang T, Valdes E, Frontera JA. Levetiracetam for seizure prophylaxis in neurocritical care: a systematic review and meta-analysis. Neurocrit Care. 2022;36(1):248–58.
pubmed: 34286461
doi: 10.1007/s12028-021-01296-z
Valdes E, Fang T, Boffa M, Frontera JA. Optimal dosing of levetiracetam for seizure prophylaxis in critically ill patients: a prospective observational study. Crit Care Med. 2023;6:66.
Jones FJS, Sanches PR, Smith JR, Zafar SF, Blacker D, Hsu J, et al. Seizure prophylaxis after spontaneous intracerebral hemorrhage. JAMA Neurol. 2021;78(9):1128–36.
pubmed: 34309642
doi: 10.1001/jamaneurol.2021.2249
Kong THJ, Abdul Azeem M, Naeem A, Allen S, Kim JA, Struck AF. Epileptiform activity predicts epileptogenesis in cerebral hemorrhage. Ann Clin Transl Neurol. 2022;9(9):1475–80.
pubmed: 36030385
pmcid: 9463945
doi: 10.1002/acn3.51637
Kim JA, Boyle EJ, Wu AC, Cole AJ, Staley KJ, Zafar S, et al. Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy. Ann Neurol. 2018;83(4):858–62.
pubmed: 29537656
pmcid: 5912971
doi: 10.1002/ana.25211